Jiuzhitang Co., Ltd.

SZSE:000989 Stock Report

Market Cap: CN¥6.7b

Jiuzhitang Past Earnings Performance

Past criteria checks 3/6

Jiuzhitang has been growing earnings at an average annual rate of 5.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 4.1% per year. Jiuzhitang's return on equity is 6.6%, and it has net margins of 9.4%.

Key information

5.5%

Earnings growth rate

5.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-4.1%
Return on equity6.6%
Net Margin9.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Weak Statutory Earnings May Not Tell The Whole Story For Jiuzhitang (SZSE:000989)

Nov 07
Weak Statutory Earnings May Not Tell The Whole Story For Jiuzhitang (SZSE:000989)

Recent updates

Jiuzhitang Co., Ltd.'s (SZSE:000989) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Nov 14
Jiuzhitang Co., Ltd.'s (SZSE:000989) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Weak Statutory Earnings May Not Tell The Whole Story For Jiuzhitang (SZSE:000989)

Nov 07
Weak Statutory Earnings May Not Tell The Whole Story For Jiuzhitang (SZSE:000989)

Investors Aren't Buying Jiuzhitang Co., Ltd.'s (SZSE:000989) Earnings

Sep 30
Investors Aren't Buying Jiuzhitang Co., Ltd.'s (SZSE:000989) Earnings

Jiuzhitang (SZSE:000989) Seems To Use Debt Rather Sparingly

Jun 26
Jiuzhitang (SZSE:000989) Seems To Use Debt Rather Sparingly

Revenue & Expenses Breakdown

How Jiuzhitang makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:000989 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,6542491,170152
30 Jun 242,8222571,241150
31 Mar 242,7122381,201150
31 Dec 232,9612971,318145
30 Sep 232,9402551,314145
30 Jun 232,9632341,352152
31 Mar 232,9263971,327147
01 Jan 233,0333581,357142
30 Sep 223,2563921,382127
30 Jun 223,5954201,540119
31 Mar 223,8352871,651111
01 Jan 223,7842711,677118
30 Sep 213,8903151,739116
30 Jun 213,8052951,689123
31 Mar 213,8132911,693121
31 Dec 203,5602721,570113
30 Sep 203,4932311,596110
30 Jun 203,3282131,53099
31 Mar 203,1442011,46394
31 Dec 193,1841921,519102
30 Sep 192,9661911,387105
30 Jun 193,0501861,487107
31 Mar 193,2562751,64596
31 Dec 183,1623361,51885
30 Sep 183,6345411,74781
30 Jun 183,8606861,82191
31 Mar 183,9917311,87291
31 Dec 173,8377211,76970
30 Sep 173,4957031,48540
30 Jun 173,1907101,2220
31 Mar 172,7616549090
31 Dec 162,6746528660
30 Sep 162,1455726780
30 Jun 161,7235544790
31 Mar 161,2714902890
31 Dec 158724711380
31 Dec 147984031480

Quality Earnings: 000989 has high quality earnings.

Growing Profit Margin: 000989's current net profit margins (9.4%) are higher than last year (8.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 000989's earnings have grown by 5.5% per year over the past 5 years.

Accelerating Growth: 000989's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 000989 had negative earnings growth (-2.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 000989's Return on Equity (6.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 09:12
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiuzhitang Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li WuTianfeng Securities Brokerage Co., Ltd